Connection
Thomas Henthorn to Treatment Outcome
This is a "connection" page, showing publications Thomas Henthorn has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.006 |
|
|
|
-
Troiani T, Serkova NJ, Gustafson DL, Henthorn TK, Lockerbie O, Merz A, Long M, Morrow M, Ciardiello F, Eckhardt SG. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res. 2007 Nov 01; 13(21):6450-8.
Score: 0.006